|買盤||0.00 x 0|
|賣出價||0.00 x 0|
|今日波幅||309.30 - 314.50|
|52 週波幅||274.00 - 349.45|
|Beta 值 (5 年，每月)||0.19|
|市盈率 (最近 12 個月)||18.48|
|每股盈利 (最近 12 個月)||17.02|
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies evaluating crovalimab compared to eculizumab, a current standard of care in paroxysmal nocturnal hemoglobinuria (PNH), were presented at the European Hematology Association Hybrid Congress. In the COMMODORE 2 study, 79.3% of participants randomized to be treated with crovalimab achieved hemolysis control from week five to week 25 compared with 79.0% with AstraZeneca Plc's (NASDAQ: AZN) Soliris (eculizum
Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib significantly reduced magnetic resonance imaging (MRI) markers of MS disease activity in the brain compared to placebo. Additionally, pre-clinical data have shown fenebrutinib to be potent and highly selective, and it is the only reversible inhibitor currently in Phase 3 trials for MS. Fenebrutinib s
Investors can find growth plays in many corners of the stock market, but a smart play would be looking for the stocks reshaping the future. These are companies at the forefront of a burgeoning trend that look poised to run away with a large slice of the growing market share. A good first place to look is at the population as a whole. Unfortunately, we’re getting older and more unhealthy. The WHO estimates that 1 in 6 people will be over 60 by 2030. By 2050, the proportion of the population that’
Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency) to CHF 15.3 billion on falling demand for COVID-19 therapies and diagnostics kits. Excluding COVID-19, Roche's sales grew 8%. Pharmaceuticals Division sales were up 9% to CHF 11.7 billion. The eye medicine Vabysmo, launched in early 2022, became the division's biggest growth driver, generating CHF 432 million in Q1 sales. Related: FDA Approves Roche's Polivy Combo Therapy For Untreated Patients Wit
The FDA has approved Roche Group AG's (OTC: RHHBY) Genentech's Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for previously untreated diffuse large B-cell lymphoma (DLBCL). The approval covers DLBCL patients not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of two or greater. Polivy combination is the first FDA-approved therapy in nearly 20
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains. What Happened: SAB-176 is produced using SAB's proprietary DiversitAb platform, which enables rapid, scalable production of highly potent, fully-human polyclonal IgG antibodies without human donors. Data from previously completed trials indicate that SAB-176
Health investment and innovation has been on a roller coaster as a result of the pandemic. But the momentum needs to continue, according to Michael Milken.
華潤醫藥(03320)宣布，旗下華潤醫藥商業與羅氏製藥中國正式簽署戰略合作協議，雙方將共同推廣抗流感創新藥物速福達®（瑪巴羅沙韋片），通過創新模式的探索，進一步提高其在中國市場的可及性，惠及更多中國流感患者。速福達® 於2021年4月在中國正式獲批，用於治療12周歲及以上急性無併發症的流感患者，包括存在流感併發症高風險的患者，並在獲批上市八個月後即被納入國家醫保目錄。 (ST)
Roche (OTC: RHHBY) announces collaboration with Eli Lilly and Company (NYSE: LLY) to support the development of its Elecsys Amyloid Plasma Panel (EAPP). The EAPP is a blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease. If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis. Also Read: New Four
Roche Holdings AG (OTC: RHHBY) announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study. Data confirm that increases in motor function were sustained at four years, and the overall rate of adverse events continued to decrease over the 48 months, reinforcing the long-term efficacy and safety of Evrysdi. Participants also reported continuous improvement or stabilization when independently perfo
Exelixis Inc (NASDAQ: EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 is sponsored by Roche Holdings AG (OTC: RHHBY) and co-funded by Exelixis. The study evaluated Cabometyx (cabozantinib) combined with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear or non-clear renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy. Three months ago, t
Blueprint Medicines Corporation (NASDAQ: BPMC) will regain global commercialization and development rights to Gavreto (pralsetinib), excluding Greater China, following a decision by Roche Holdings AG (OTC: RHHBY) to discontinue the collaboration agreement for strategic reasons. The termination will be effective 12 months from the notification date of Feb. 22, 2023. Blueprint Medicines will explore options to advance and simplify the continued global commercialization and development of Gavreto.
Roche Holdings AG (OTC: RHHBY) announced new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) at 24 weeks. The studies showed that treatment with Vabysmo resulted in early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains compared to treatment with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Eylea (aflibercept). Vabysmo als
Roche Holdings AG (OTC: RHHBY) has announced results from the global phase 3 COMMODORE 2 study, evaluating the efficacy and safety of crovalimab in treatment-naive people with paroxysmal nocturnal hemoglobinuria (PNH). The study met its co-primary efficacy endpoints of transfusion avoidance and control of hemolysis (the ongoing destruction of red blood cells measured by lactate dehydrogenase levels). Also Read: Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics.
Roche Holdings AG (OTC: RHHBY) released FY22 sales growth of 2% (+1% in CHF) to CHF 63.3 billion. Core operating profit increased by 3% (+1% in CHF), reflecting the good underlying business performance. The company warned that in 2023, a sharp decline in COVID-19 products would knock sales by around CHF 5 billion. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the company said. Related: FDA Approves Roche's Tocilizumab As First Monoclona
Roche Holding Ltd (OTC: RHHBF) (OTC: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. The XBB.1.5 Omicron sub-variant is prevalent in the U.S. and quickly spreads to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment stra
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study evaluates Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tecentriq combination showed a statistically significant improvement in RFS in t
The European Commission has approved Roche Holdings AG's (OTC: RHHBY) Xofluza (baloxavir marboxil) in children aged one year and above for uncomplicated influenza and post-exposure prophylaxis of influenza. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus. The approval is based on the results of the phase 3 miniSTONE-2 and BLOCKSTONE studies. The miniSTONE-2 study met its primary endpoint of safety and showed that
In this article, we will take a look at the 15 biggest non-tech companies in the world by market cap. To see more such companies, go to 5 Biggest Non-Tech Companies in the World by Market Cap. Easy monetary policies, tech revolution, disposable income and societal changes after the coronavirus pandemic injected a euphoria-like optimism […]
The FDA has accepted Roche Holdings AG's (OTC: RHHBY) Biologics License Application (BLA) and granted priority review for glofitamab for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. LBCL is an aggressive (fast-growing) type of non-Hodgkin lymphoma (NHL) and is one of the most prevalent types of blood cancer among adults in the U.S. The FDA is expected to decide on the approval of this novel cancer immunotherapy by 1 July 2023. Related: Ro
The FDA approved Roche Holding AG (OTC: RHHBY) unit Genentech's Lunsumio (mosunetuzumab-axgb) for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate, making Lunsumio the first CD20xCD3 bispecific to be authorized for this form of non-Hodgkin lymphoma (NHL). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a
The FDA approved Roche Holdings AG's (OTC: RHHBY) Actemra (tocilizumab) intravenous (IV) for COVID-19 in hospitalized adult patients. Roche said that the drug was approved for COVID patients receiving certain steroids and who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or life support equipment extracorporeal membrane oxygenation. Actemra is the first FDA-approved monoclonal antibody to treat COVID-19 and is recommended for use as a single 60-minute IV infusion.
Roche Holdings AG (OTC: RHHBY) announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were presented at the American Society of Hematology Annual Meeting & Exposition. Updated data from the pivotal phase 2 NP30179 study in relapsed or refractory large B-cell lymphoma (R/R LBCL) showed glofitamab given as a fixed course induced early and durable responses that were maintained beyond the end of treatment. Most patients who ha
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU U.S. chipmaker Broadcom Inc's (NASDAQ: AVGO) $61 billion Vmware, Inc (NYSE: VMW) deal could hit a roadblock with EU antitrust regulators poised to open a full-scale investigation into the deal. Broadcom pined for early EU approval of the deal by highlighting competition from Amazon.com Inc (NASDAQ: AMZN), Microsoft Corp (NASDAQ: MSFT), and Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google in the cloud computing market.
Roche Holdings AG's (OTC: RHHBY) head of its pharmaceuticals division, Bill Anderson, has decided to leave after 16 years with the company. Bill Anderson would quit at the end of the year "to pursue opportunities outside of Roche," with a successor due to be named by March 2023, Roche said in a statement. Thomas Schinecker will become the ad interim CEO of Roche Pharmaceuticals starting 1 January 2023, when he hands over the CEO Roche Diagnostics role to Matt Sause as previously announced. Also